FDA Agrees to Review Cell Therapeutics, Inc. Application

Xconomy.com -- Cell Therapeutics, the Seattle-based developer of cancer drugs, said today that the FDA has agreed to review the company’s application to market pixantrone for non-Hodgkin’s lymphoma in the U.S.